What was the total amount of senior notes issued by Amgen?

Amgen issued a total of $4.0 billion in aggregate principal amount of Senior Notes across four different maturity series.

What are the intended uses for the proceeds from this note offering?

The filing states the net proceeds are expected to be approximately $3.95 billion. While not explicitly detailed for specific uses, proceeds from such offerings are typically used for general corporate purposes, which may include funding operations, research and development, capital expenditures, strategic investments, or potential acquisitions.

How do these new notes rank in Amgen's capital structure?

The Notes will rank equal in right of payment to all of Amgen's other existing and future senior unsecured indebtedness. They rank senior to any existing and future subordinated indebtedness, but are effectively subordinated to the obligations of Amgen's subsidiaries and subordinated to Amgen's secured obligations to the extent of the assets securing such obligations.

What happens to the notes in case of a change of control at Amgen?

In the event of a change in control triggering event, as defined in the offering documents, holders of these notes have the right to require Amgen to purchase all or a portion of their notes at a price equal to 101% of the principal amount, plus any accrued and unpaid interest.

AMGN 8-K: Material Agreements

Summary

Amgen Inc. (AMGN) filed an 8-K on February 22, 2022, announcing the successful issuance and sale of a substantial amount of senior notes. The company raised approximately $3.95 billion in net proceeds from the offering, which included four tranches of notes with varying interest rates and maturity dates: 3.000% Senior Notes due 2029, 3.350% Senior Notes due 2032, 4.200% Senior Notes due 2052, and 4.400% Senior Notes due 2062. These notes are unsecured and rank equally with other senior unsecured indebtedness, but are effectively subordinated to subsidiary obligations and senior to any subordinated debt. The proceeds from this offering are expected to bolster Amgen's financial flexibility, potentially for general corporate purposes, including funding operations, investments, and future strategic initiatives. This debt issuance provides Amgen with long-term capital at fixed rates, which could be utilized for ongoing research and development, capital expenditures, or potential acquisitions.

Key Highlights

1Amgen Inc. successfully issued and sold $4.0 billion in aggregate principal amount of Senior Notes.
2Net proceeds from the offering amounted to approximately $3.95 billion after deducting underwriting discounts and estimated expenses.
3The issuance comprises four tranches: 3.000% Notes due 2029, 3.350% Notes due 2032, 4.200% Notes due 2052, and 4.400% Notes due 2062.
4The notes will pay interest semi-annually, with the first payment due on August 22, 2022.
5The notes are unsecured and rank equally with existing and future senior unsecured indebtedness.
6A change in control triggering event allows noteholders to require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest.

AMGEN INC 8-K Report, Material Agreement (Feb 22, 2022)

Summary

Key Highlights

Frequently Asked Questions